Aberrant expression of CXCR4 and β-catenin in pancreatic cancer

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 4103-4110

  Wang, Zheng ^a   Ma, Qingyong ^a   Li, Pei ^a   Sha, Huanchen ^a   Li, Xuqi ^a   Xu, Jun ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

catenin; CXCR4; Pancreatic cancer; Tumor progression

Indexed keywords

BETA CATENIN; CHEMOKINE RECEPTOR CXCR4;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

Β-CATENIN; CXCR4; PANCREATIC CANCER; TUMOR PROGRESSION;

AGED; BASE SEQUENCE; BETA CATENIN; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CXCR4; SURVIVAL ANALYSIS;

EID: 84884995251     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
3. Gil M, Seshadri M, Komorowski MP, Abrams SI and Kozbor D: Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci USA 110: E1291-1300, 2013.
4. Woo SU, Bae JW, Kim CH, Lee JB and Koo BW: A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol 15: 281-285, 2008.
5. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG and Walenkamp AM: A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer 49: 219-230, 2013.
6. Balkwill FR: The chemokine system and cancer. J Pathol 226: 148-157, 2012.
7. Busillo JM and Benovic JL: Regulation of CXCR4 signaling. Biochim Biophys Acta 1768: 952-963, 2007.
8. Burger JA and Kipps TJ: CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767, 2006.
9. Parker CC, Kim RH, Li BD and Chu QD: The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients. J Surg Oncol 106: 393-398, 2012.
10. Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K, Hanazono K, Owaki T and Aikou T: Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncol Rep 21: 65-71, 2009.
11. Shanmugam MK, Manu KA, Ong TH, Ramachandran L, Surana R, Bist P, Lim LH, Kumar AP, Hui KM and Sethi G: Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int J Cancer 129: 1552-1563, 2011.
12. Leelawat K, Leelawat S, Narong S and Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 13: 1561-1568, 2007.
13. Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Devière J, Salmon I and Van Laethem JL: High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 100: 1444-1451, 2009.
14. Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, Mantovani A and Allavena P: Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 64: 8420-8427, 2004.
15. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
16. Yang F, Zeng Q, Yu G, Li S and Wang CY: Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal 18: 679-687, 2006.
17. White BD, Chien AJ and Dawson DW: Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 142: 219-32, 2012.
18. Saadeddin A, Babaei-Jadidi R, Spencer-Dene B and Nateri AS: The links between transcription, β-catenin/JNK signaling, and carcinogenesis. Mol Cancer Res 7: 1189-1196, 2009.
19. Pujal J, Capella G and Real FX: The Wnt pathway is active in a small subset of pancreatic cancer cell lines. Biochim Biophys Acta 1762: 73-79, 2006.
20. Luo Y, Cai J, Xue H, Mattson MP and Rao MS: SDF1alpha/ CXCR4 signaling stimulates beta-catenin transcriptional activity in rat neural progenitors. Neurosci Lett 398: 291-295, 2006.
21. Wang Z, Ma Q, Liu Q, Yu H, Zhao L, Shen S and Yao J: Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer 99: 1695-1703, 2008.
22. Wang Z and Ma Q: β-Catenin is a promising key factor in the SDF-1/CXCR4 axis on metastasis of pancreatic cancer. Med Hypotheses 69: 816-820, 2007.
23. Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. New York, NY: Springer; 2010.
24. Leo C, Horn LC, Rauscher C, Hentschel B, Liebmann A, Hildebrandt G and Höckel M: Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 12: 6894-6900, 2006.
25. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR and Welch DR: Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 21: 761-767, 2009.
26. Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, Yamori T, Tsuruo T, Kawabe T, Miyagishi M, Taira K, Sata M and Omata M: Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65: 5864-5871, 2009.
27. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T, Fujii N and Imamura M: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin Cancer Res 6: 3530-3535, 2000.
28. Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S and Ramage JM: The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer 106: 1306-1313, 2012.
29. Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM and Chu QD: Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 141: 53-59, 2007.
30. Lee HS, Park MH, Yang SJ, Park KC, Kim NS, Kim YS, Kim DI, Yoo HS, Choi EJ and Yeom YI: Novel candidate targets of Wnt/β-catenin signaling in hepatoma cells. Life Sci 80: 690-698, 2007.
31. Wang L, Cheng H, Liu Y, Wang L, Yu W, Zhang G, Chen B, Yu Z and Hu S: Prognostic value of nuclear β-catenin overexpression at invasive front in colorectal cancer for synchronous liver metastasis. Ann Surg Oncol 18: 1553-1559, 2011
32. Yu X, Wang Y, DeGraff DJ, Wills ML and Matusik RJ: Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30: 1868-79, 2011.
33. Hsu HP, Shan YS, Jin YT, Lai MD and Lin PW: Loss of Ecadherin and β-catenin is correlated with poor prognosis of ampullary neoplasms.J Surg Oncol 101: 356-62, 2010.